Programs in Clinical Trial
or Registration
We prioritize our R&D efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, rare diseases, and biosimilars. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is researching and developing unique therapies that will matter most to the people we serve.
As of February 27, 2015
![](assets/images/science/pipeline/pipeline_part0.png)
![](assets/images/science/pipeline/pipeline_part1.png)
![](assets/images/science/pipeline/pipeline_part2.png)
![](assets/images/science/pipeline/pipeline_part3.png)
![](assets/images/science/pipeline/pipeline_part4.png)
![](assets/images/science/pipeline/pipeline_part5.png)
View the latest pipeline on pfizer.com
![](assets/images/videos/schiffman.jpg)
Q: How does Pfizer choose what medicines to focus R&D efforts on?
Julie Schiffman
Portfolio & Decision Analysis
![](assets/images/footer/back_to_top.png)